[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumocystis-jirovecii-pneumonia-in-non-hiv-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumocystis-jirovecii-pneumonia-in-non-hiv-patients":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100645666","tmp-smx-for-non-hiv-pcp-a-prospective-multicenter-study-100645666",false,"NCT07690410","TMP-SMX for Non-HIV PCP: A Prospective Multicenter Study","Efficacy and Safety of TMP-SMX for Non-HIV-Related PCP: A Prospective Multicenter Observational Study","Inclusion Criteria:\n\n* Age ≥18 years,\n* Meet the diagnostic criteria for Non-HIV-associated PCP,\n* Receiving TMP\u002FSMX as the initial treatment for PCP,\n* Provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women,\n* History of severe allergy or documented intolerance to TMP\u002FSMX,\n* TMP\u002FSMX used for PCP prophylaxis rather than treatment,\n* TMP\u002FSMX treatment duration \\\u003C72 hours at the time of screening,\n* TMP\u002FSMX administered at a supratherapeutic dose (TMP component \\>20 mg\u002Fkg\u002Fday).","ALL","18 Years",{"count":19,"type":20},480,"ESTIMATED","OBSERVATIONAL","Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection in immunocompromised patients. Non-HIV-related PCP has a rising incidence, faster progression, and higher mortality than HIV-associated cases. Trimethoprim-sulfamethoxazole (TMP\u002FSMX) is first-line, but standard dosing (TMP 15-20 mg\u002Fkg\u002Fday) is associated with adverse reaction rates of 56%-72%, and prospective evidence is scarce. This prospective, multicentre, observational study aims to compare the efficacy and safety of low-dose (TMP \\\u003C15 mg\u002Fkg\u002Fday) versus conventional-dose TMP\u002FSMX for non-HIV-related PCP, and to explore the value of therapeutic drug monitoring in individualising therapy, without interfering with routine clinical decisions.\n\nThe investigators plan to enrol 480 patients aged ≥18 years with confirmed non-HIV-related PCP receiving TMP\u002FSMX as initial treatment, excluding those with allergy, prophylaxis, treatment \\\u003C72 hours, or supratherapeutic dosing. The primary outcome is treatment failure at day 21 (all-cause death or new invasive ventilation). Secondary outcomes include day-8 oxygenation change, 30- and 90-day mortality, regimen completion, adverse events (CTCAE v6.0), and hospital\u002FICU stay. Propensity score matching will be the main analysis, with inverse probability weighting for sensitivity.",[24],"Pneumocystis Jirovecii Pneumonia in Non-HIV Patients",[26,27,28,29,30],"Trimethoprim-Sulfamethoxazole","Prospective Studies","Multicenter Study","Pneumocystis jirovecii","Pneumonia","NOT_YET_RECRUITING","2026-07-12",{"date":34,"type":35},"2026-07-14","ACTUAL",{"date":37,"type":20},"2026-08-01",{"date":39,"type":20},"2029-06-30",{"name":41,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER"]